Compare CORT & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | BIO |
|---|---|---|
| Founded | 1998 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.0B |
| IPO Year | 2001 | 1994 |
| Metric | CORT | BIO |
|---|---|---|
| Price | $111.91 | $357.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $96.50 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.3M | 297.8K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ 0.09 | N/A |
| Revenue | $761,407,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $26.08 | $2.74 |
| Revenue Next Year | $26.98 | $3.20 |
| P/E Ratio | $1,267.14 | ★ $9.72 |
| Revenue Growth | ★ 12.79 | 0.65 |
| 52 Week Low | $28.66 | $236.73 |
| 52 Week High | $122.21 | $355.85 |
| Indicator | CORT | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 74.55 |
| Support Level | $76.41 | $290.67 |
| Resistance Level | $122.21 | N/A |
| Average True Range (ATR) | 5.21 | 11.43 |
| MACD | 0.55 | 2.87 |
| Stochastic Oscillator | 72.40 | 97.11 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.